Comparison of non-myeloablative conditioning regimens for lymphoproliferative disorders

S. Hong, Jennifer Le-Rademacher, A. Artz, Pl McCarthy, B. Logan, M. Pasquini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hematopoietic cell transplantation (HCT) with non-myeloablative (NMA) conditioning for lymphoproliferative diseases (LD) includes fludarabine with and without low-dose TBI. Transplant outcomes were compared among patients aged ≥40 years with LD who received a HCT with TBI (N = 382) or no-TBI (N = 515) NMA from 2001 to 2011. The groups were comparable except for donor, graft, prophylaxis for GVHD, disease status and year of HCT. Cumulative incidences of grades II-IV GVHD at 100 days were 29% and 20% (P = 0.001) and of chronic GVHD at 1 year were 54% and 44% (P = 0.004) for TBI and no-TBI, respectively. Multivariate analysis of progression/relapse, treatment failure and mortality showed no outcome differences by conditioning. Full donor chimerism at day 100 was observed in 82% vs 64% in the TBI and no-TBI groups, respectively (P = 0.006). Subsets of the four most common conditioning/GVHD prophylaxis combinations demonstrated higher rates of grades II-IV acute (P<0.001) and chronic GVHD (P<0.001) among recipients of TBI-mycophenolate mofetil (MMF) compared with other combinations. TBI-based NMA conditioning induces faster full donor chimerism, but overall survival outcomes are comparable to no-TBI regimens. Combinations of TBI and MMF are associated with higher rates of GVHD without impact on survival outcomes in patients with LD.

Original languageEnglish (US)
Pages (from-to)367-374
Number of pages8
JournalBone Marrow Transplantation
Volume50
Issue number3
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Lymphoproliferative Disorders
Cell Transplantation
Mycophenolic Acid
Chimerism
Tissue Donors
Transplants
Survival
Treatment Failure
Multivariate Analysis
Recurrence
Mortality
Incidence

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Comparison of non-myeloablative conditioning regimens for lymphoproliferative disorders. / Hong, S.; Le-Rademacher, Jennifer; Artz, A.; McCarthy, Pl; Logan, B.; Pasquini, M.

In: Bone Marrow Transplantation, Vol. 50, No. 3, 01.01.2015, p. 367-374.

Research output: Contribution to journalArticle

Hong, S. ; Le-Rademacher, Jennifer ; Artz, A. ; McCarthy, Pl ; Logan, B. ; Pasquini, M. / Comparison of non-myeloablative conditioning regimens for lymphoproliferative disorders. In: Bone Marrow Transplantation. 2015 ; Vol. 50, No. 3. pp. 367-374.
@article{fed585851fa24aafb648690f72dd5bb5,
title = "Comparison of non-myeloablative conditioning regimens for lymphoproliferative disorders",
abstract = "Hematopoietic cell transplantation (HCT) with non-myeloablative (NMA) conditioning for lymphoproliferative diseases (LD) includes fludarabine with and without low-dose TBI. Transplant outcomes were compared among patients aged ≥40 years with LD who received a HCT with TBI (N = 382) or no-TBI (N = 515) NMA from 2001 to 2011. The groups were comparable except for donor, graft, prophylaxis for GVHD, disease status and year of HCT. Cumulative incidences of grades II-IV GVHD at 100 days were 29{\%} and 20{\%} (P = 0.001) and of chronic GVHD at 1 year were 54{\%} and 44{\%} (P = 0.004) for TBI and no-TBI, respectively. Multivariate analysis of progression/relapse, treatment failure and mortality showed no outcome differences by conditioning. Full donor chimerism at day 100 was observed in 82{\%} vs 64{\%} in the TBI and no-TBI groups, respectively (P = 0.006). Subsets of the four most common conditioning/GVHD prophylaxis combinations demonstrated higher rates of grades II-IV acute (P<0.001) and chronic GVHD (P<0.001) among recipients of TBI-mycophenolate mofetil (MMF) compared with other combinations. TBI-based NMA conditioning induces faster full donor chimerism, but overall survival outcomes are comparable to no-TBI regimens. Combinations of TBI and MMF are associated with higher rates of GVHD without impact on survival outcomes in patients with LD.",
author = "S. Hong and Jennifer Le-Rademacher and A. Artz and Pl McCarthy and B. Logan and M. Pasquini",
year = "2015",
month = "1",
day = "1",
doi = "10.1038/bmt.2014.269",
language = "English (US)",
volume = "50",
pages = "367--374",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Comparison of non-myeloablative conditioning regimens for lymphoproliferative disorders

AU - Hong, S.

AU - Le-Rademacher, Jennifer

AU - Artz, A.

AU - McCarthy, Pl

AU - Logan, B.

AU - Pasquini, M.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Hematopoietic cell transplantation (HCT) with non-myeloablative (NMA) conditioning for lymphoproliferative diseases (LD) includes fludarabine with and without low-dose TBI. Transplant outcomes were compared among patients aged ≥40 years with LD who received a HCT with TBI (N = 382) or no-TBI (N = 515) NMA from 2001 to 2011. The groups were comparable except for donor, graft, prophylaxis for GVHD, disease status and year of HCT. Cumulative incidences of grades II-IV GVHD at 100 days were 29% and 20% (P = 0.001) and of chronic GVHD at 1 year were 54% and 44% (P = 0.004) for TBI and no-TBI, respectively. Multivariate analysis of progression/relapse, treatment failure and mortality showed no outcome differences by conditioning. Full donor chimerism at day 100 was observed in 82% vs 64% in the TBI and no-TBI groups, respectively (P = 0.006). Subsets of the four most common conditioning/GVHD prophylaxis combinations demonstrated higher rates of grades II-IV acute (P<0.001) and chronic GVHD (P<0.001) among recipients of TBI-mycophenolate mofetil (MMF) compared with other combinations. TBI-based NMA conditioning induces faster full donor chimerism, but overall survival outcomes are comparable to no-TBI regimens. Combinations of TBI and MMF are associated with higher rates of GVHD without impact on survival outcomes in patients with LD.

AB - Hematopoietic cell transplantation (HCT) with non-myeloablative (NMA) conditioning for lymphoproliferative diseases (LD) includes fludarabine with and without low-dose TBI. Transplant outcomes were compared among patients aged ≥40 years with LD who received a HCT with TBI (N = 382) or no-TBI (N = 515) NMA from 2001 to 2011. The groups were comparable except for donor, graft, prophylaxis for GVHD, disease status and year of HCT. Cumulative incidences of grades II-IV GVHD at 100 days were 29% and 20% (P = 0.001) and of chronic GVHD at 1 year were 54% and 44% (P = 0.004) for TBI and no-TBI, respectively. Multivariate analysis of progression/relapse, treatment failure and mortality showed no outcome differences by conditioning. Full donor chimerism at day 100 was observed in 82% vs 64% in the TBI and no-TBI groups, respectively (P = 0.006). Subsets of the four most common conditioning/GVHD prophylaxis combinations demonstrated higher rates of grades II-IV acute (P<0.001) and chronic GVHD (P<0.001) among recipients of TBI-mycophenolate mofetil (MMF) compared with other combinations. TBI-based NMA conditioning induces faster full donor chimerism, but overall survival outcomes are comparable to no-TBI regimens. Combinations of TBI and MMF are associated with higher rates of GVHD without impact on survival outcomes in patients with LD.

UR - http://www.scopus.com/inward/record.url?scp=84938416290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938416290&partnerID=8YFLogxK

U2 - 10.1038/bmt.2014.269

DO - 10.1038/bmt.2014.269

M3 - Article

C2 - 25437248

AN - SCOPUS:84938416290

VL - 50

SP - 367

EP - 374

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -